Green carbon footprintIn September, Unilever announced a €1bn investment to improve the sustainability of its cleaning brands from the ground up. European Biotechnology spoke to Dr Neil Parry, R&D programme director … more ➔
The role of investors in addressing AMRAbigail Herron from Aviva Investors describes why AMR is a blind spot for investors and which action is needed to change it. more ➔
Protection in case of SPCs for pharmaceuti... SPCs offer up to five and a half years of additional protection after patent expiration for pharmaceuticals in order to compensate the patent holder’s inability to exploit their inventions while products … more ➔
Rentschler Biopharma expands U.S. footprin... Prior to Danish Genmab A/S’s recent licence option deal with AbbVie Inc, Rentschler Biopharma has extended its collaboration with Genmab. European Biotechnology spoke with Rentschler Biopharma SE’s … more ➔
The road to recovery goes via vaccines and...If reopening the economy after the prolonged shutdown was the end of the beginning, then the successful development of vaccines and therapeutic antibodies has the potential to be the beginning of the … more ➔
Product hopping Boon or Bane? Intellectual Property Providing access to medicines at affordable prices while maintaining incentives for the originators to invest into significant innovations is a balance that’s hard to find. Product … more ➔
Product hopping – Boon or Bane? Intellectual Property Providing access to medicines at affordable prices while maintaining incentives for the originators to invest into significant innovations is a balance that’s hard to find. Product … more ➔
Expansion through partnershipsImmatics Biotechnologies has landed a potential US$1.1bn deal with GlaxoSmithKline (GSK) to find novel cancer targets on solid tumours and to direct TCR-T cell therapies against them. European Biotechnology … more ➔
European assets ahead despite virus panicEvery year, it’s the same: in January, investors are scratching their heads, searching to find investment ideas that could ensure the greatest return/performance. Given the current valuation, can 2020 … more ➔
Is your reality quite different from other... While open innovation may be seen as a way of cutting costs by shutting down in-house R&D in favour of promoting spin-offs, start-ups, and biotech SMEs, the open science movement aims to establish … more ➔
